At EHL Bio
All employees are working on developing technology to culture adipose tissue-derived mesenchymal stem cells, and are committed to research & development, and production of immunotherapeutic agents.
EHL Bio has set up a production facility that meets GMP standards for the mass production of stem cell and immune cell therapeutics to treat intractable diseases; and clinical trials are underway to improve the quality of life for patients.
In addition, by establishing medical clusters both domestically and internationally, we are striving to promote healthy living worldwide through joint research and cooperation with leading global companies.
EHL Bio is committed to overcoming diseases through constant research and effort for the bright and healthy future of humankind.
| Date of Establishment | 21st February, 2012 |
| CEO | Hong-gi Lee |
| Address | B 411-412 Indeogwon IT Valley, 40 Imi-ro, Uiwang-si, Gyeonggi-do (Headquarters, Research Institute, GMP Center) 8 401 Seocho-daero 1-gil, Seocho-gu, Seoul |
| Major Business |
|